Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | DDX3X | O00571 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19434692 | 1.00 | KDM4E (0.58) | KDM4ESMN1; SMN2LMNAUSP2NPSR1 | |
| SCHEMBL19434701 | 0.83 | KMT2A (0.59) | KDM4ESMN1; SMN2LMNAUSP2NPSR1 | |
| SCHEMBL19434700 | 0.83 | KMT2A (0.59) | KDM4ESMN1; SMN2LMNAUSP2NPSR1 | |
| SCHEMBL11898668 | 0.77 | KMT2A (0.83) | KDM4ESMN1; SMN2LMNAUSP2NPSR1 | |
| SCHEMBL11898667 | 0.77 | KMT2A (0.83) | KDM4ESMN1; SMN2LMNAUSP2NPSR1 | |
| SCHEMBL17561007 | 0.77 | DDX3X (0.68) | SMN1; SMN2LMNANPSR1GAAMAPT | |
| SCHEMBL17561004 | 0.77 | DDX3X (0.68) | SMN1; SMN2LMNANPSR1GAAMAPT | |
| SCHEMBL1444576 | 0.74 | MAPT (0.69) | KDM4ESMN1; SMN2LMNANPSR1GAA | |
| SCHEMBL11961917 | 0.74 | MAPT (0.69) | KDM4ESMN1; SMN2LMNANPSR1GAA | |
| SCHEMBL19434681 | 0.74 | MAPT (0.56) | KDM4ESMN1; SMN2LMNAUSP2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3960729-A1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | Neoculi Pty Ltd (AU) | 2022-03-02 | — | — | EP | claimed |
| US-10370341-B2 | Compounds and methods of treating infections | NEOCULI PTY LTD (AU) | 2019-08-06 | — | — | US | claimed |
| US-10253002-B2 | Compounds and methods of treating infections | NEOCULI PTY LTD (AU) | 2019-04-09 | — | — | US | claimed |
| US-20190084941-A1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | NEOCULI PTY LTD (AU) | 2019-03-21 | — | — | US | claimed |
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2017-10-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084941-A1 | COMPOUNDS AND METHODS OF TREATING INFECTIONS | ELANE, IL1A, IL1B | KDM4E 3245/4885SMN1; SMN2 3440/4885LMNA 3006/4885 |
| US-10370341-B2 | Compounds and methods of treating infections | ELANE, IL1A, IL1B | KDM4E 3245/4885SMN1; SMN2 3440/4885LMNA 3006/4885 |
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | DPM1, ABCB11, PIGS | KDM4E 3521/4885SMN1; SMN2 3002/4885LMNA 2337/4885 |
| US-10253002-B2 | Compounds and methods of treating infections | ELANE, IL1A, IL1B | KDM4E 3245/4885SMN1; SMN2 3440/4885LMNA 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.